SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully- human polyclonal antibodies, has appointed Carlos Carrillo, PhD, as senior vice president, regulatory affairs.
Dr. Carrillo brings over 25 years of experience managing regulatory strategy in the biopharmaceutical industry, along with CMC and process development expertise. He has held global leadership roles in regulatory affairs and project management at a number of biopharmaceutical and healthcare companies. Prior to joining SAB, he was director, regulatory affairs at Sagent Pharmaceuticals, where he was responsible for communicating with the FDA and providing guidance to the discovery, process development, quality and manufacturing teams.
Earlier, Dr. Carrillo worked as director, regulatory affairs/product portfolio at Johnson Matthey Pharma Ventures, where he managed regulatory assessments of CMC changes and executed regulatory planning and implementation. Before that, he was director, regulatory affairs/project management at Wockhardt and global project management at Fresenius Kabi.
Dr. Carrillo has additionally held roles at Hospira, Metrics, and Abbott Laboratories. He received his PhD in Regulatory Law and Policy of Drug Products, Medical Devices, Biologics and his MS in Drug Product Development, Patent and Intellectual Law, both from Northeastern University.